BACKGROUND: Adrenaline-producing tumors are mostly characterized by a sudden release of catecholamines with episodic symptoms. Noradrenergic ones are usually less symptomatic and characterized by a continuous overproduction of catecholamines that are released into the bloodstream. Their effects on the cardiovascular system can thus be different. The aim of this study was to determine the prevalence of cardiovascular complications by catecholamine phenotype. METHODS: We retrospectively analyzed data on the prevalence of cardiovascular events in 341 consecutive patients with pheochromocytoma and paraganglioma treated from 1995 to 2023. Biochemical catecholamine phenotype was determined based on plasma or urinary catecholamines and metanephrines. RESULTS: According to the phenotype, 153 patients had noradrenergic pheochromocytoma and paraganglioma and 188 had adrenergic pheochromocytoma and paraganglioma. In the whole sample, the incidence of serious cardiovascular complications was 28% (95 patients), with no difference between the phenotypes or sexes. The noradrenergic phenotype had significantly more atherosclerotic complications (composite end point of type 1 myocardial infarction and symptomatic peripheral artery disease; odds ratio, 3.58 [95% CI, 1.59-8.83]; P=0.003), while the adrenergic phenotype more often had type 2 myocardial infarction and takotsubo-like cardiomyopathy (OR, 0.24 [95% CI, 0.09-0.57]; P=0.002). These changes remained even after adjustment for conventional risk factors of atherosclerosis. CONCLUSIONS: We found a 28% incidence of cardiovascular complications in a consecutive group of patients with pheochromocytoma and paraganglioma. Patients presenting with a noradrenergic phenotype have a higher incidence of atherosclerotic complications, while the adrenergic phenotype is associated with a higher incidence of acute myocardial damage due to takotsubo-like cardiomyopathy.
- MeSH
- adrenergní látky MeSH
- ateroskleróza * komplikace MeSH
- fenotyp MeSH
- feochromocytom * diagnóza MeSH
- infarkt myokardu * MeSH
- kardiomyopatie * MeSH
- katecholaminy MeSH
- lidé MeSH
- metanefrin MeSH
- nádory nadledvin * patologie MeSH
- paragangliom * komplikace MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Currently, with the knowledge of the role of collateral circulation in the development of cerebral ischaemia, traditional therapeutic windows are being prolonged, with time not being the only criterion. Instead, a more personalised approach is applied to select additional patients who might benefit from active treatment. This review briefly describes the current knowledge of the pathophysiology of the development of early ischaemic changes, the capabilities of MRI to depict such changes, and the basics of the routinely used imaging techniques broadly available for the assessment of individual phases of cerebral ischaemia, and summarises the possible clinical use of routine MR imaging, including patient selection for active treatment and assessment of the outcome on the basis of imaging.
- MeSH
- cerebrální infarkt MeSH
- cévní mozková příhoda * diagnostické zobrazování terapie MeSH
- difuzní magnetická rezonance metody MeSH
- edém mozku * MeSH
- ischemická cévní mozková příhoda * MeSH
- ischemie mozku * diagnostické zobrazování terapie MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
AIMS: Heart failure-related cardiogenic shock (HF-CS) accounts for a significant proportion of CS cases. Whether patients with de novo HF and those with acute-on-chronic HF in CS differ in clinical characteristics and outcome remains unclear. The aim of this study was to evaluate differences in clinical presentation and mortality between patients with de novo and acute-on-chronic HF-CS. METHODS AND RESULTS: In this international observational study, patients with HF-CS from 16 tertiary care centres in five countries were enrolled between 2010 and 2021. To investigate differences in clinical presentation and 30-day mortality, adjusted logistic/Cox regression models were fitted. Patients (n = 1030) with HF-CS were analysed, of whom 486 (47.2%) presented with de novo HF-CS and 544 (52.8%) with acute-on-chronic HF-CS. Traditional markers of CS severity (e.g. blood pressure, heart rate and lactate) as well as use of treatments were comparable between groups. However, patients with acute-on-chronic HF-CS were more likely to have a higher CS severity and also a higher mortality risk, after adjusting for relevant confounders (de novo HF 45.5%, acute-on-chronic HF 55.9%, adjusted hazard ratio 1.38, 95% confidence interval 1.10-1.72, p = 0.005). CONCLUSION: In this large HF-CS cohort, acute-on-chronic HF-CS was associated with more severe CS and higher mortality risk compared to de novo HF-CS, although traditional markers of CS severity and use of treatments were comparable. These findings highlight the vast heterogeneity of patients with HF-CS, emphasize that HF chronicity is a relevant disease modifier in CS, and indicate that future clinical trials should account for this.
- MeSH
- kardiogenní šok * etiologie MeSH
- lidé MeSH
- mortalita v nemocnicích MeSH
- prognóza MeSH
- srdeční selhání * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
BACKGROUND: Currently, use of mechanical circulatory support (MCS) in non-ischaemic cardiogenic shock (CS) is predominantly guided by shock-specific markers, and not by markers of cardiac function. We hypothesise that left ventricular ejection fraction (LVEF) can identify patients with a higher likelihood to benefit from MCS and thus help to optimise their expected benefit. METHODS: Patients with non-ischaemic CS and available data on LVEF from 16 tertiary-care centres in five countries were analysed. Cox regression models were fitted to evaluate the association between LVEF and mortality, as well as the interaction between LVEF, MCS use and mortality. RESULTS: N = 807 patients were analysed: mean age 63 [interquartile range (IQR) 51.5-72.0] years, 601 (74.5%) male, lactate 4.9 (IQR 2.6-8.5) mmol/l, LVEF 20 (IQR 15-30) %. Lower LVEF was more frequent amongst patients with more severe CS, and MCS was more likely used in patients with lower LVEF. There was no association between LVEF and 30-day mortality risk in the overall study cohort. However, there was a significant interaction between MCS use and LVEF, indicating a lower 30-day mortality risk with MCS use in patients with LVEF ≤ 20% (hazard ratio 0.72, 95% confidence interval 0.51-1.02 for LVEF ≤ 20% vs. hazard ratio 1.31, 95% confidence interval 0.85-2.01 for LVEF > 20%, interaction-p = 0.017). CONCLUSION: This retrospective study may indicate a lower mortality risk with MCS use only in patients with severely reduced LVEF. This may propose the inclusion of LVEF as an adjunctive parameter for MCS decision-making in non-ischaemic CS, aiming to optimise the benefit-risk ratio.
- MeSH
- funkce levé komory srdeční MeSH
- kardiogenní šok * diagnóza terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- podpůrné srdeční systémy * MeSH
- retrospektivní studie MeSH
- senioři MeSH
- tepový objem MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVES: Peripheral venoarterial extracorporeal membrane oxygenation (ECMO) with femoral access is obtained through unilateral or bilateral groin cannulation. Whether one cannulation strategy is associated with a lower risk for limb ischemia remains unknown. We aim to assess if one strategy is preferable. DESIGN: A retrospective cohort study based on the Extracorporeal Life Support Organization registry. SETTING: ECMO centers worldwide included in the Extracorporeal Life Support Organization registry. PATIENTS: All adult patients (≥ 18 yr) who received peripheral venoarterial ECMO with femoral access and were included from 2014 to 2020. INTERVENTIONS: Unilateral or bilateral femoral cannulation. MEASUREMENTS AND MAIN RESULTS: The primary outcome was the occurrence of limb ischemia defined as a composite endpoint including the need for a distal perfusion cannula (DPC) after 6 hours from implantation, compartment syndrome/fasciotomy, amputation, revascularization, and thrombectomy. Secondary endpoints included bleeding at the peripheral cannulation site, need for vessel repair, vessel repair after decannulation, and in-hospital death. Propensity score matching was performed to account for confounders. Overall, 19,093 patients underwent peripheral venoarterial ECMO through unilateral ( n = 11,965) or bilateral ( n = 7,128) femoral cannulation. Limb ischemia requiring any intervention was not different between both groups (bilateral vs unilateral: odds ratio [OR], 0.92; 95% CI, 0.82-1.02). However, there was a lower rate of compartment syndrome/fasciotomy in the bilateral group (bilateral vs unilateral: OR, 0.80; 95% CI, 0.66-0.97). Bilateral cannulation was also associated with lower odds of cannulation site bleeding (bilateral vs unilateral: OR, 0.87; 95% CI, 0.76-0.99), vessel repair (bilateral vs unilateral: OR, 0.55; 95% CI, 0.38-0.79), and in-hospital mortality (bilateral vs unilateral: OR, 0.85; 95% CI, 0.81-0.91) compared with unilateral cannulation. These findings were unchanged after propensity matching. CONCLUSIONS: This study showed no risk reduction for overall limb ischemia-related events requiring DPC after 6 hours when comparing bilateral to unilateral femoral cannulation in peripheral venoarterial ECMO. However, bilateral cannulation was associated with a reduced risk for compartment syndrome/fasciotomy, lower rates of bleeding and vessel repair during ECMO, and lower in-hospital mortality.
- MeSH
- arteria femoralis MeSH
- dospělí MeSH
- ischemie etiologie MeSH
- kompartment syndrom * MeSH
- lidé MeSH
- mimotělní membránová oxygenace * metody MeSH
- mortalita v nemocnicích MeSH
- periferní katetrizace * metody MeSH
- retrospektivní studie MeSH
- rizikové faktory MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: There are dated and conflicting data about the optimal timing of initiation of P2Y12 inhibitors in elective percutaneous coronary intervention (PCI). Peri-PCI myocardial necrosis is associated with poor outcomes. We aimed to assess the impact of the P2Y12 inhibitor loading time on periprocedural myocardial necrosis in the population of the randomized Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting (ALPHEUS) trial, which compared ticagrelor with clopidogrel in high-risk patients who received elective PCI. METHODS: The ALPHEUS trial divided 1809 patients into quartiles of loading time. The ALPHEUS primary outcome was used (type 4 [a or b] myocardial infarction or major myocardial injury) as well as the main secondary outcome (type 4 [a or b] myocardial infarction or any type of myocardial injury). RESULTS: Patients in the first quartile group (Q1) presented higher rates of the primary outcome (P = 0.01). When compared with Q1, incidences of the primary outcome decreased in patients with longer loading times (adjusted odds ratio [adjOR], 0.70 [0.52.-0.95]; P = 0.02 for Q2; adjOR 0.65 [0.48-0.88]; P < 0.01 for Q3; adjOR 0.66 [0.49-0.89]; P < 0.01 for Q4). Concordant results were found for the main secondary outcome. There was no interaction with the study drug allocated by randomization (clopidogrel or ticagrelor). Bleeding complications (any bleeding ranging between 4.9% and 7.3% and only 1 major bleeding at 48 hours) and clinical ischemic events were rare and did not differ among groups. CONCLUSIONS: In elective PCI, administration of the oral P2Y12 inhibitor at the time of PCI could be associated with more frequent periprocedural myocardial necrosis than an earlier administration. The long-term clinical consequences remain unknown.
- MeSH
- infarkt myokardu * etiologie MeSH
- inhibitory agregace trombocytů terapeutické užití MeSH
- klopidogrel terapeutické užití MeSH
- koronární angioplastika * metody MeSH
- lidé MeSH
- purinergní receptory P2Y - antagonisté terapeutické užití MeSH
- ticagrelor terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- MeSH
- infarkt myokardu * epidemiologie terapie MeSH
- lidé MeSH
- nemocnice MeSH
- poskytování zdravotní péče MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Background Coronary artery calcium (CAC) has prognostic value for major adverse cardiovascular events (MACE) in asymptomatic individuals, whereas its role in symptomatic patients is less clear. Purpose To assess the prognostic value of CAC scoring for MACE in participants with stable chest pain initially referred for invasive coronary angiography (ICA). Materials and Methods This prespecified subgroup analysis from the Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease (DISCHARGE) trial, conducted between October 2015 and April 2019 across 26 centers in 16 countries, focused on adult patients with stable chest pain referred for ICA. Participants were randomly assigned to undergo either ICA or coronary CT. CAC scores from noncontrast CT scans were categorized into low, intermediate, and high groups based on scores of 0, 1-399, and 400 or higher, respectively. The end point of the study was the occurrence of MACE (myocardial infarction, stroke, and cardiovascular death) over a median 3.5-year follow-up, analyzed using Cox proportional hazard regression tests. Results The study involved 1749 participants (mean age, 60 years ± 10 [SD]; 992 female). The prevalence of obstructive coronary artery disease (CAD) at CT angiography rose from 4.1% (95% CI: 2.8, 5.8) in the CAC score 0 group to 76.1% (95% CI: 70.3, 81.2) in the CAC score 400 or higher group. Revascularization rates increased from 1.7% to 46.2% across the same groups (P < .001). The CAC score 0 group had a lower MACE risk (0.5%; HR, 0.08 [95% CI: 0.02, 0.30]; P < .001), as did the 1-399 CAC score group (1.9%; HR, 0.27 [95% CI: 0.13, 0.59]; P = .001), compared with the 400 or higher CAC score group (6.8%). No significant difference in MACE between sexes was observed (P = .68). Conclusion In participants with stable chest pain initially referred for ICA, a CAC score of 0 showed very low risk of MACE, and higher CAC scores showed increasing risk of obstructive CAD, revascularization, and MACE at follow-up. Clinical trial registration no. NCT02400229 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Hanneman and Gulsin in this issue.
- MeSH
- bolesti na hrudi diagnostické zobrazování MeSH
- dospělí MeSH
- infarkt myokardu * MeSH
- lidé středního věku MeSH
- lidé MeSH
- nemoci koronárních tepen * diagnostické zobrazování MeSH
- vápník MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- randomizované kontrolované studie MeSH
Cíl: Ischemická choroba srdeční se v průběhu času mění. Není známo, jak se změnila ischemická choroba dolních končetin. Metodika, soubor: Z dokumentace naší ordinace jsme vybrali nemocné s ischemickou chorobou dolních končetin. Nemocní byli vyšetřeni klinicky, duplexní sonografií a byl změřen krevní tlak nad kotníky a vyjádřen jako index kotník-paže (ABI). Při dalších kontrolách jsme sledovali vývoj klinického stavu. Za zhoršení jsme považovali zhoršení intermitentních klaudikací anebo vznik kritické končetinové ischemie. Naše nálezy jsme porovnali s výsledky prací dřívějších i nynějších. Výsledky: Do souboru jsme zařadili 406 nemocných, ženy tvořily 38,7 %. U všech nemocných byla příčinou ateroskleróza. Průměrný věk činil 69,5 roku (rozmezí 40–90), 75 % mělo hypertenzní nemoc, 33 % diabetes mellitus, 53,5 % kouřilo. Revaskularizace v anamnéze udávalo 14 % nemocných. Intermitentní klaudikace udávalo 63 %. Déle než jeden rok, v průměru 5,6 roku, jsme sledovali 189 nemocných. Měli podobný věk a rizikové faktory jako celý soubor. Ke klinickému zhoršení došlo u 15,9 % pacientů. Klaudikace se zhoršily u 13,2 %, kritická ischemie vznikla u 5,3 % a amputace u 1,06 %. Revaskularizace byly provedeny u 28 % nemocných. Z celého souboru zemřelo 144 pacientů, z toho 43,7 z kardiovaskulárních příčin a 27,1 na nádorová onemocnění. Závěr: Ischemická choroba dolních končetin postihuje stále starší osoby a přibývá žen. Mají vyšší výskyt rizikových faktorů aterosklerózy než nemocní s ischemickou chorobou srdeční. Díky současné péči, jistě ne optimální, je průběh onemocnění mírnější než před 50 lety. U našich pacientů se klaudikace zhoršovaly méně často a klesl počet amputací. Podíl kardiovaskulárních chorob na úmrtí pacientů s ischemickou chorobou dolních končetin se snížil.
Objective: Coronary artery disease changes over time. It is unknown how the peripheral artery disease of the legs has changed. Methods, the group: We used the medical records of our office to select patients with peripheral artery disease of the legs. The patients underwent clinical assessments including duplex sonography, and their blood pressure at the ankle was measured and expressed as ABI index. Further development of the clinical condition was then followed at subsequent visits. Worsening was defined as worsening of intermittent claudication and/or development of critical limb ischemia. We compared our findings to the results of previous as well as current studies. Results: The group comprised 406 patients including 38.7% females. Atherosclerosis was the cause of the disease in all patients. Mean age was 69.5 years (range 40-90); 75% patients had hypertension, 33% had diabetes mellitus, and 53.5% were smokers. History of revascularization was reported by 14% patients. Intermittent claudication was reported by 63% patients. We followed 189 patients for more than 1 year, 5.6 years on average. Their age and risk factors were similar to those of the entire group. Clinical worsening was experienced by 15.9% patients. Claudication worsened in 13.2% patients, critical ischemia occurred in 5.3% and amputation in 1.06%. Revascularization was performed in 28% patients. One hundred forty-four patients of the entire group died; of these, 43.7 died from cardiovascular causes and 27.1 of cancer. Conclusion: Peripheral artery disease of the legs affects persons of higher age compared to previous times and the proportion of women has increased. The patients show a higher rate of risk factors of atherosclerosis compared to those with coronary artery disease. Thanks to the current care, although certainly not optimal, the course of the disease is less severe than 50 years ago. In our patients, claudication worsening was observed less commonly and the rate of amputations decreased. The number of deaths attributable to cardiovascular diseases in patients with peripheral artery disease of the legs has decreased.
- MeSH
- amputace MeSH
- ateroskleróza diagnóza etiologie komplikace MeSH
- chronická kritická ischemie končetin * diagnostické zobrazování diagnóza komplikace prevence a kontrola MeSH
- dospělí MeSH
- intermitentní klaudikace etiologie MeSH
- ischemická choroba srdeční diagnóza komplikace MeSH
- kardiovaskulární nemoci prevence a kontrola MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- klinická studie MeSH
Ruptura mezikomorového septa (ventricular septal rupture, VSR) představuje jednu z možných mechanických komplikací po akutním infarktu myokardu (AIM). I když se s ní nelze setkat často, je spojena se zvýšenou mortalitou. U většiny pacientů lze pozorovat aktivní klinické projevy, u menšího procenta z nich však místo toho dochází k dalšímu tichému rozvoji s nástupem subakutního srdečního selhání (heart failure, HF) nebo s dekompenzací. Po stanovení diagnózy je naprosto nezbytné urychleně zahájit léčbu. Nutná je léčba farmakologická (tzn. podávání anti-ischemické medikace včetně léčiv snižujících afterload) spolu s definitivní korekcí, buď intervenční, nebo chirurgickou, protože neprovedení korekce VSR vede neodvratně k úmrtí. Mnoho rozvojových zemí nicméně trpí omezeným přístupem ke zdravotní péči; výsledkem je opožděná nebo nedostatečná lékařská péče. Popisujeme případ starší ženy s dekompenzovaným HF v důsledku ruptury apikálního septa, u níž se v důsledku několika problémů – nesouvisejících se zdravotní péčí – prováděla pouze farmakologická léčba a která uvedené komplikaci nakonec podlehla.
Ventricular septal rupture (VSR) constitutes one of the possible mechanical complications following an acute myocardial infarction (AMI), even though very infrequent, it bears an elevated high mortality rate. Although most patients develop florid clinical manifestations, a minority might have a silent evolution, experiencing a subacute heart failure (HF) onset or decompensation instead. Once identified, prompt treatment is mandatory. Management, consistent of medical therapy (i.e.; anti-ischemic and afterload reducing medications) along with definite repair, either through interventional or surgical technique, is necessary, since if uncor- rected, VSR ultimately leads to death. However, many developing countries face an inadequate healthcare access, resulting in delayed and impoverished medical attention. We present the case of an elderly woman with decompensated HF due to an apical VSR, and as a result of several extra-medical issues, only medical therapy was established, and as feared, she succumbed to the disease.
- MeSH
- infarkt myokardu komplikace MeSH
- kardiovaskulární nemoci epidemiologie klasifikace komplikace MeSH
- lidé středního věku MeSH
- lidé MeSH
- mezikomorová přepážka patologie MeSH
- rizikové faktory MeSH
- ruptura komorového septa * diagnóza etiologie farmakoterapie mortalita MeSH
- srdeční selhání etiologie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
- Geografické názvy
- Amerika MeSH